新里程收盘下跌1.32%，滚动市盈率67.68倍，总市值75.88亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of New Mile Health Technology Group Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1][2] - As of July 30, the closing price of New Mile was 2.24 yuan, down 1.32%, with a rolling PE ratio of 67.68 times and a total market capitalization of 7.588 billion yuan [1] - The average PE ratio for the healthcare service industry is 48.15 times, with a median of 61.34 times, positioning New Mile at the 33rd rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that New Mile achieved an operating revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.6519 million yuan, down 9.35% [1] - The gross profit margin for sales was reported at 27.96% [1] - The company has been focused on drug production for over 20 years, with its main products being pharmaceuticals and medical services, particularly the "Duyiwei" brand of traditional Chinese medicine [1]